Research company Chosa Oncology has established operations in Boston, Massachusetts, as part of the company’s commercialization plan for the biomarker platform Platin-DRP in the US market. The presence is intended to strengthen relationships with clinical partners, laboratories, pharmaceutical companies, investors and other potential partners. As a first step, the company plans to offer Platin-DRP as a Research Use Only test for researchers, pharmaceutical companies and clinical partners. CEO Peter Buhl Jensen describes the initiative as an important milestone for the future US launch.